Cancer

CareDx to Acquire Oncology Diagnostics Company Naveris for $160 Million

CareDx will acquire Naveris for $160 million, adding a Medicare-reimbursed liquid biopsy platform for viral-mediated cancer monitoring to its precision medicine portfolio.

Cancer

Blood Test Predicts Metastatic Risk in Bladder Cancer Patients Who Keep Their Bladders

Circulating tumor DNA testing may help predict metastatic risk in muscle-invasive bladder cancer patients opting for bladder-sparing treatment, according to Fox Chase Cancer Center researchers, though additional biomarkers are needed for local recurrence.

Cancer

Blood Test Shows Promise for Detecting Glioblastoma Using microRNA Signatures

A study identified microRNA patterns in blood plasma that could support noninvasive diagnosis and monitoring of the most aggressive form of brain cancer.

GeneCentric Data Suggest Fragmentomics Could Expand Liquid Biopsy Beyond Mutation Testing

Apr 15, 2026 | Cancer, Company News, Molecular Diagnostics

Presentations at AACR 2026 will showcase fragmentomics-based technology for detecting therapeutic markers and providing prognostic insight.

NeoGenomics to Spotlight AI-Driven Genomic–Clinical Data Integration at AACR 2026

Apr 15, 2026 | Cancer, Digital Pathology, Molecular Diagnostics

Presentations at the upcoming annual meeting will focus on AI-based analysis, biomarker prevalence, and therapy development.

Labcorp and Children’s Hospital of Philadelphia Partner to Expand Pediatric Diagnostic Access

Apr 14, 2026 | Cancer, Company News, Diagnostic Technologies

The collaboration aims to create an innovation pipeline for specialized pediatric tests across oncology, metabolic disease, and autoimmune conditions.

Ataraxis AI Launches Test to Predict Response to Neoadjuvant Therapy in Breast Cancer

Apr 10, 2026 | Breast

The tool uses digitized pathology slides to estimate how patients will respond to therapy before surgery.

Blood-Based Biomarker Identifies Cancer Risk in Lynch Syndrome Patients

Apr 9, 2026 | Cancer

Researchers at MD Anderson have identified a blood-based biomarker using T cell receptor sequencing that may help assess cancer risk in asymptomatic Lynch syndrome carriers, according to a study in Nature Communications.

FDA Clears At-Home Cervical Cancer Screening Tool

Apr 8, 2026 | Cervical (HPV)

The clearance of the Onclarity HPV Self-Collection Kit and approval of the BD Onclarity HPV Assay aim to reduce barriers for unscreened populations.

Multi-Cancer Early Detection Test Added to Evexia Diagnostics Platform

Apr 7, 2026 | Cancer

20/20 BioLabs’ AI-powered multi-cancer early detection test, OneTest for Cancer, is now available to approximately 40,000 clinicians via the Evexia Diagnostics platform.

New Research on Automated Myeloid Testing and Molecular Residual Disease to be Presented at AACR 2026

Apr 7, 2026 | Cancer, Lung Cancer, Molecular Diagnostics

Biodesix will present seven abstracts—including two oral sessions—at AACR 2026, highlighting advances in automated myeloid testing, liquid biopsy, and NGS-based cancer monitoring platforms.

DecisionDx-Melanoma Gene Expression Test Improves Risk Prediction Beyond Standard Staging

Apr 6, 2026 | Melanoma

Data from nearly 1,900 SEER-linked patients show the test identifies meaningful survival differences within the same AJCC stage.

EpiCapture Urine-Based Prostate Cancer Test Shows High Accuracy in Clinical Study

Apr 6, 2026 | Prostate

The updated urine test utilizes machine learning and patient ethnicity to provide individualized risk scores for aggressive disease.

Home HPV Self-Sampling Kits Show Promise for Closing Cervical Screening Gap in Disabled Women

Apr 2, 2026 | Cervical (HPV)

A new survey-based study finds that more than half of physically Disabled women would prefer at-home human papillomavirus testing over traditional clinic-based cervical screening.

Urine-Based Liquid Biopsy Shows High Sensitivity for Prostate Cancer Detection

Apr 2, 2026 | Prostate

A new study validates a machine-learning platform that detects prostate cancer through biochemical patterns in urine samples.

New Whole Genome and Transcriptome Assay Launches for Myeloid Malignancies

Apr 2, 2026 | Leukemia

Caris Life Sciences has launched Caris ChromoSeq, a whole genome and transcriptome sequencing assay for myeloid malignancies, designed to consolidate multiple tests into a single workflow with a seven-day turnaround.

Blood Test Using Inflammatory Biomarkers Advances for Colorectal Cancer Detection

Mar 31, 2026 | Colorectal

Irish researchers have secured €670,000 to clinically validate a blood-based colorectal cancer screening test using inflammatory biomarkers, aiming for launch by 2027 through a new spin-out company.

Molecular Test Detects Bile Duct Cancer at Twice the Rate of Standard Methods

Mar 31, 2026 | Cancer, Molecular Diagnostics

The BiliSeq molecular test detected bile duct cancer in 82% of cases—compared to 44% with standard pathology—according to a six-year, multi-institutional study.

Category: Cancer

Cancer

Cancer

Cancer